Owen Mumford and Stevanato strike agreement on Aidaptus auto-injector
Owen Mumford, a company which designs, develops and manufactures injectable drug delivery systems for the pharmaceutical, biotech and generics industries, has signed an exclusive agreement with Stevanato Group, a provider of drug containment, drug delivery and diagnostic solutions for the Aidaptus auto-injector.
The agreement makes Stevanato Group an exclusive manufacturing partner for the Owen Mumford designed auto-injector, offering a full set of capabilities to its pharmaceutical customers.
Stevanato Group will mould the components for Aidaptus and provide final and sub-assembly equipment, while also offering market-leading pre-filled syringes to enable pharmaceutical customers to create the final product for patient use. Assembly of the components will be undertaken by both Stevanato Group at its global manufacturing sites and by Owen Mumford at its automated assembly centre of excellence in the UK.
The collaboration is intended to bring added value to customers, matching device expertise with manufacturing capabilities.
Aidaptus is a two-step, single use auto-injector with a design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features plunger sensing technology with a self-adjusting plunger rod that adapts to the individual plunger positions and different fill volumes in each syringe, with no change parts required. The auto-injector can accommodate a variety of drug viscosities.
Owen Mumford designs and manufactures medical products that are designed to meet both the needs of pharmaceutical companies and their patients, by facilitating ease of use and improving safety and patient compliance. The company designs devices with the aim of reducing complexity and risk for the pharmaceutical and biotech industry in the development of combination products.
Adam Mumford, director of Owen Mumford, said: “Aidaptus will help patients to self-administer their individual therapies using a simple and easy to use device. At the same time, this auto-injector can help to reduce complexity, minimise supply chain risk and simplify final assembly for pharmaceutical and biotechnology companies thanks to its ability to adapt to different viscosity, syringe sizes and fill volumes. Often during development or life-cycle management of injectable drug products, changes in these parameters can occur. Now for the first time, the device does not have to be changed as well.”
Mauro Stocchi, chief business officer of Stevanato Group, added: "We believe this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market. As we are constantly working with our customers to satisfy their needs, we continue to experience an increase in demand for auto-injectors. With this agreement, we will exploit the full breadth of Stevanato Group integrated capabilities being able to offer device manufacturing, assembly equipment, together with pre-fillable syringes and inspection systems."